FDA Issues Urgent Warning About Rare Allergic Reactions Linked to Multiple Sclerosis Drug Copaxone
The U.S. Food and Drug Administration (FDA) has issued a stark warning about a rare but potentially life-threatening allergic reaction associated with certain multiple sclerosis (MS) drugs, including Teva Pharmaceuticals’ Copaxone. The agency is adding a boxed warning, its most prominent safety alert, to highlight the risk of anaphylaxis, a severe allergic reaction that can occur at any time during treatment.
Glatiramer acetate, the active ingredient in Copaxone, is a widely prescribed medication for patients with relapsing-remitting multiple sclerosis, a chronic condition affecting the central nervous system. While the drug has been a cornerstone in MS treatment for decades, the FDA’s latest findings underscore the importance of vigilance among patients and healthcare providers.
What Is Anaphylaxis and How Does It Manifest?
Anaphylaxis is a rapid-onset allergic reaction that can be fatal if not treated immediately. According to the FDA, symptoms such as wheezing, difficulty breathing, swelling of the face or throat, and hives can escalate quickly to more severe conditions like shock or severe rash.
The agency reported that 82 cases of anaphylaxis linked to glatiramer acetate were identified globally between December 1996 and May 2024. Alarmingly, 19 of these cases occurred more than a year after patients began treatment. Most patients experienced symptoms within one hour of injection, and six fatalities were recorded.
A Closer Look at the Drugs Involved
Copaxone, marketed by Teva, is one of the most recognizable names in MS treatment. Though, a generic version of the drug, Glatopa, is also available and sold by Sandoz. Both medications are administered via injection, either daily or three times a week, depending on the dosage.
The FDA emphasized that anaphylaxis can occur after the first dose or even years into treatment, making it critical for patients to remain alert to potential symptoms.
What Should Patients Do?
The FDA advises patients to seek immediate medical attention if they experience any symptoms of an allergic reaction after administering the medication. This is especially crucial if symptoms are more than mild, worsen over time, or fail to resolve quickly.
Key Takeaways: A Summary Table
| Key Information | Details |
|—————————————–|—————————————————————————–|
| Drugs Affected | Copaxone (Teva), Glatopa (Sandoz) |
| Active Ingredient | Glatiramer acetate |
| Condition Treated | Relapsing-remitting multiple sclerosis |
| Risk Highlighted | Anaphylaxis (severe allergic reaction) |
| Timeframe of Risk | Can occur after first dose or years into treatment |
| Reported Cases (1996–2024) | 82 worldwide, including 19 cases after >1 year of treatment |
| Fatalities | 6 |
| Common Symptoms | Wheezing, swelling, hives, difficulty breathing |
| FDA Advice | Seek immediate medical attention for severe or worsening symptoms |
The Broader Implications
This warning serves as a reminder of the importance of monitoring for adverse effects, even with long-standing medications. While glatiramer acetate has helped countless patients manage their MS symptoms, the potential for severe allergic reactions cannot be overlooked.
Patients currently using Copaxone or Glatopa are encouraged to discuss this new warning with their healthcare providers to ensure they are prepared to recognize and respond to any signs of anaphylaxis.